MiMedx Q1 Revenue Forecast at $70m and EPS Loss of $0.03; 2026 Outlook Cut
MiMedx Group is expected to report Q1 revenue of $70m and a per-share loss of $0.03, while full-year 2026 revenue forecasts have fallen from $400m to $310m. Analysts project one-year price targets averaging $8, implying 140% upside, even as earnings estimates for 2026 plunged from $0.27 to $0.07 per share.
1. Earnings Preview
MiMedx Group is scheduled to release Q1 2026 results on April 29, with consensus forecasts calling for $70 million in revenue and a per-share loss of $0.03.
2. Estimate Revisions
Over the past three months, full-year 2026 revenue estimates for MiMedx have fallen from $400 million to $310 million, and EPS forecasts have been cut from $0.27 to $0.07; 2027 estimates show similar declines from $460 million to $340 million in revenue and from $0.40 to $0.19 in EPS.
3. Q4 Results Recap
In Q4 2025, MiMedx delivered $120 million in revenue, beating expectations by 10.6%, and reported EPS of $0.10 versus $0.088 forecast, although the stock slipped 6.44% the following day.
4. Analyst Outlook
Analysts’ one-year price targets range from $6.00 to $10.00, averaging $8.00 for a 140% upside, while brokerage consensus rates MiMedx as an Outperform with an average recommendation of 2.0.